Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial.
Brabus Launches ‘Deep Blue’ G-Wagon, Speedboat & Luxury Watch Line
Brabus is unifying its collaborations with Mercedes-AMG, Finland’s Axopar Boats, and Panerai luxury watches under one Deep Blue collection.Being that Brabus is...
